Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  Treatment
Treatment/Intervention:  antibody-drug conjugate therapy
Results 1-25 of 97 for your search:
Start Over
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: C25001, NCI-2012-01066, 2010-024215-14, NCT01578499
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BO27952, NCI-2013-00507, 2012-000660-22, NCT01641939
Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: C25003, NCI-2012-03101, 12/LO/1950, 2011-005450-60, JapicCTI-142491, U1111-1161-4937, NCT01712490
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: SGN35-014, NCI-2013-00462, 2012-002751-42, NCT01777152
A Study Comparing Kadcyla Plus Perjeta Treatment to Chemotherapy Combined With Herceptin Plus Perjeta in Patients With HER2-Positive Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BO28408, NCI-2014-01818, NCT02131064
Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients with Newly Diagnosed Hodgkin Lymphoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Supportive care, Treatment
Age: 18 and younger
Trial IDs: AHOD1331, NCI-2014-01223, NCT02166463
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Older Patients with Previously Untreated Acute Lymphoblastic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 60 and over
Trial IDs: 2010-0991, NCI-2011-01123, NCT01371630
Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 18
Trial IDs: C25002, NCI-2012-01146, 2011-001240-29, U1111-1158-2613, NCT01492088
Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IM-T-hLL1-DOX-02, NCI-2013-00484, NCT01585688
Dose Finding Study of Once or Twice Weekly IMMU-130 in Metastatic Colorectal Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IM-T-IMMU-130-02, NCI-2013-01786, NCT01605318
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IM-T-IMMU-132-01, NCI-2014-00136, NCT01631552
BT062 in Combination With Lenalidomide/Dexamethasone in Patients With Multiple Myeloma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 983, NCI-2012-02101, NCT01638936
Brentuximab Vedotin and Bendamustine Hydrochloride in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: AAAJ5050, NCI-2012-01926, NCT01657331
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients with Stage II-IV HIV-Associated Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AMC-085, NCI-2013-00046, 085, 2014-003678-18, PAMC-085_A05PAMDREVW01, NCT01771107
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients with Relapsed or Refractory Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 to 30
Trial IDs: AHOD1221, NCI-2013-00107, COG-AHOD1221, NCT01780662
Brentuximab Vedotin and Rituximab in Treating Patients with Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 12H09, NCI-2012-03090, STU00072695, NCT01805037
Moxetumomab Pasudotox in Treating Patients with Relapsed and/or Refractory Acute Lymphoblastic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2012-1143, NCI-2013-02207, NCT01891981
SC16LD6.5 in Recurrent Small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: SCRX16-001, NCI-2014-00483, NCT01901653
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Untreated Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma or Gray Zone Lymphomas
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 17413, NCI-2013-02359, 818280, NCT01994850
Brentuximab Vedotin with or without Azacitidine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0706, NCI-2014-01114, NCT02096042
Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9111, NCI-2014-01782, NCT02227199
Start Over